BALAXI PHARMACEUTICALS share price
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.71down ₹0.62 (3.05%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹20.33.
29 Oct: open ₹20.60, high ₹20.60, low ₹19.16
52-week range of traded prices to 29 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹109 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.88
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.44
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,01671.2% delivered
Results
Standalone, as consolidated accounts are on record for only 7 of the last ten years; ₹ crore.BALAXI PHARMACEUTICALS quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −5.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −87.2%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹16 Crdown 23.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹1.25 CrQuarter to Mar 2026: ₹0.16 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −8.0%
Revenue by quarter
Peak revenue ₹25 Cr, quarter to Dec 2025; lowest ₹9.65 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in the quarter to Jun 2026, −₹1.25 CrA loss in 2 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.2 | 11.2 | 9.6 | 16.7 | 19.3 | 24.6 | 20.2 | 15.6 |
| Net profit | 1.7 | 1.7 | −1.2 | 0.2 | 3.3 | 1.5 | 0.2 | −1.3 |
| Net margin | 7.9% | 15.6% | −12.2% | 1.2% | 16.9% | 6.2% | 0.8% | −8.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹81 Crup 32.57%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5.15 Crup 42.92%
- Net margin
- 6.4%
Revenue by year
Peak revenue ₹108 Cr, year to Mar 2023; lowest ₹0.00 Cr, year to Mar 2018
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 9 years shown
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 14 | 46 | 87 | 101 | 108 | 70 | 61 | 81 |
| Net profit | −1 | 2 | 6 | 15 | 15 | 16 | 4 | 4 | 5 |
| Net margin | – | 14.5% | 14.2% | 17.4% | 14.5% | 15.0% | 5.2% | 5.9% | 6.4% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, SPECIALIZED WHOLESALE, which carries all its revenue.
Valuation
Today, against the company's own history.BALAXI PHARMACEUTICALS PE ratio and valuation
Price to earnings
At or below today's level on 90% of 991 trading days over the last 5 years.
LowestHighest
Its median11.68Industry median28.22
Price to book
At or below today's level on 2% of 928 trading days since Nov 2022.
LowestHighest
Its median2.01Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 87% of 1,951 trading days since Feb 2017.
LowestHighest
Its median0.00%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −75.5% | +43.1% | −82.9% | 0.0% |
| 3 years | −47.1% | −34.0% | −19.9% | 0.0% |
| 5 years | −31.6% | −21.0% | −13.4% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
BALAXI PHARMACEUTICALS competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to BALAXI PHARMACEUTICALS in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Speciality MedicinesSPML | 125 | 9.57 | 1.75 | – | – | 18.3% | – | 0.00% |
 Sotac PharmaceuticalsSOTAC | 118 | 20.38 | 2.00 | +0.1% | −28.2% | 10.3% | – | 0.19% |
 Makers LaboratoriesMAKERSL | 114 | 33.21 | 1.56 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Alpa LaboratoriesALPA | 111 | – | 0.59 | +0.5% | – | – | −1.8% | 0.00% |
 Tyche IndustriesTYCHE | 106 | 23.70 | 0.75 | −21.0% | −63.5% | 3.2% | −2.5% | 3.40% |
| Himalaya Nutravedics IndiaHNIL | 102 | – | – | – | – | – | – | 0.00% |
 Pharmaids PharmaceuticalsPHARMAID | 100 | – | 2.10 | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Veerhealth CareVEERHEALTH | 98 | 64.03 | 4.27 | +177.2% | +199.7% | 6.8% | 11.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.BALAXI PHARMACEUTICALS dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.10 a share, year to Mar 2022.
| Ex-date | Type | Per share |
|---|---|---|
| 1 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.BALAXI PHARMACEUTICALS announcements
Oct 2026
Sep 2026
Aug 2026
24 Aug · Management
BALAXI PHARMACEUTICALS share price by year
Each calendar year to 2025.BALAXI PHARMACEUTICALS share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 26.87 | −62.8% | 81.86 | 26.77 |
| 2024 | 72.31 | −16.4% | 142.01 | 70.12 |
| 2023 | 86.47 | −28.8% | 127.72 | 80.46 |
| 2022 | 121.44 | +18.3% | 138.35 | 67.50 |
| 2021 | 102.62 | −21.0% | 143.28 | 93.01 |
| 2020 | 129.98 | +700.4% | 208.03 | 13.54 |
| 2019 | 16.24 | +184.9% | 26.75 | 5.70 |
| 2018 | 5.70 | +91.9% | 6.02 | 2.83 |
| 2017 | 2.97 | −22.7% | 7.20 | 2.58 |
| 2016 | 3.84 | −25.1% | 5.80 | 2.36 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. The close is the year's last trade for 2018 (15 Oct 2018), 2017 (19 Dec 2017) and 2016 (8 Dec 2016).
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 20.22 | 21.20 | 19.80 | 20.33 | 20.56 | 16,375 | 83.4% |
| 27 Oct 2026 | 20.00 | 20.47 | 20.00 | 20.21 | 20.26 | 12,072 | 80.8% |
| 26 Oct 2026 | 21.10 | 21.10 | 19.50 | 19.70 | 19.85 | 24,393 | 89.1% |
| 23 Oct 2026 | 21.18 | 21.18 | 19.35 | 20.91 | 20.39 | 40,139 | 85.6% |
| 22 Oct 2026 | 21.10 | 21.30 | 19.16 | 21.00 | 20.33 | 62,006 | 65.4% |
| 21 Oct 2026 | 22.35 | 22.35 | 21.00 | 21.10 | 21.35 | 23,032 | 82.9% |
| 19 Oct 2026 | 22.09 | 22.34 | 21.60 | 21.76 | 22.01 | 19,900 | 74.8% |
| 16 Oct 2026 | 22.60 | 22.60 | 21.80 | 22.09 | 22.15 | 13,444 | 94.5% |
| 15 Oct 2026 | 22.40 | 22.62 | 21.85 | 22.13 | 22.20 | 10,714 | 76.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 30 May 2024 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- BALAXI
- ISIN
- INE618N01022
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- ANANDAMRUB
- Website
- www.balaxipharma.in